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Objective: Interleukin 6 (IL6) has the ability to influence each level of the hypothalamo-pituitary–
adrenocortical (HPA) axis. The aim of the study was to test whether IL6 concentration correlates with
the adrenal cortex response to ACTH in healthy humans. We postulated that higher basal IL6
concentration would be associated with the higher cortisol response to the stimulation.
Design and methods: Basal IL6 concentration was measured and a low dose (1 mg) ACTH test was
performed to assess cortisol response. Twenty-seven apparently healthy subjects (11 male, 16 female,
mean age 31.1 years, age range 22–47 years) were included in the study.
Results: Data are presented as meanGS.E.M. Basal IL6 level was 0.84G0.10 pg/ml. Basal cortisol was
351.9G18.3 nmol/l. Maximal cortisol during synacthen test was 653.0G20.6 nmol/l. Maximal
cortisol increment was 301.1G20.0 nmol/l. IL6 concentration was not correlated with basal or
maximal cortisol concentration, but correlated significantly with cortisol increment (rZ0.63, 95%
confidence interval) 0.42–0.83).
Conclusions: In our study, we found that higher basal IL6 concentration is associated with the higher
cortisol response to ACTH stimulation. Based on previous research and our data, IL6, even in low
concentrations and under physiologic conditions, modulates adrenal cortex responsivity to ACTH.
Therefore, it seems that immune modulation of HPA axis is also present under physiologic and not only
pathologic conditions.
European Journal of Endocrinology 159 649–652Introduction
It is well known that interleukin 6 (IL6) has the ability
to activate the hypothalamo-pituitary–adrenocortical
(HPA) axis influencing each level of the axis. IL6
stimulates corticotrophin-releasing hormone (CRH)
release from the hypothalamus of rats in a dose-
dependent manner (1, 2). IL6 also directly stimulates
corticotrophs, even in CRH knockout animals (3, 4). In
humans, acute administration of IL6 increases adreno-
corticotropin (ACTH) and cortisol concentrations (5).
Also, a dose-dependent increase in ACTH and cortisol is
seen in response to IL6 administration (6). IL6 also acts
directly on the adrenal cortex, stimulating glucocorti-
coid release. However, in the absence of ACTH, IL6 fails
to elicit glucocorticoid response. Consequently, ACTH is
a necessary permissive factor, enabling direct cytokine
actions on the adrenal gland (7).
As IL6 augments ACTH stimulation of the adrenal
cortex, higher IL6 levels should be correlated with
increased cortisol response to ACTH stimulation. In
order to test this hypothesis, we performed a low dose
(1 mg) synacthen test and measured basal IL6ndocrinologyconcentration in healthy, non-stressed humans.
Previous studies used stress (infection or exercise), or
direct infusion of IL6 to assess its effects on HPA axis.
However, we decided to analyse the influence of non-
stimulated IL6 level and to vary ACTH concentration.Materials and methods
Subjects
Twenty-seven apparently healthy subjects (11 male, 16
female, mean age 31.1 years, age range 22–47 years,
mean body mass index (BMI) 23.5 kg/m2, BMI range
17.1–28.9 kg/m2) were included in the study. Inclusion
criteria were: i) normal renal and liver function tests, ii)
no intercurrent disease in the last three weeks, iii) no
signs of endocrine dysfunction, iv) not taking any drugs,
v) normal C-reactive protein (CRP) level and vi) normal
arterial blood pressure. Subjects were instructed to have
a good rest and at least 8 h sleep before the test. Ethical
approval was obtained, and all participants gave
informed consent.DOI: 10.1530/EJE-08-0544
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Figure 1 Relation between IL6 and Dcortisol. Circles represent
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After a twelve-hour fast, blood was sampled for cortisol
determination. An indwelling venous catheterwas placed
in the antecubital vein 30 min before the start of the test.
The lowdose synacthen test started at0800 hwith the i.v.
injection of 1 mg synacthen (Novartis Pharma Schweiz).
Blood samples for cortisol determination were taken from
the i.v. cannula at 0, 15 and 30 min. The blood sample for
IL6 determination was taken at 0 min. All blood samples
were immediately separated and kept frozen at K80 8C
until assayed.
As previously described, for the low dose test a vial of
250 mg synacthen was diluted in normal saline solution
to a concentration of 0.5 mg/ml (8). The solution was
used immediately.males and triangles females. Regression lines are drawn and
represent all subjects (solid line), males (dashed line) and females
(dotted line).Assays
IL6 was determined using enzyme immunoassay tech-
nique (Quantikine HS, R&D Systems Inc., Minneapolis,
MN, USA) with intra- and interassay coefficient of
variation (CV) of 6.9–7.4 and 6.5–9.6% respectively.
Cortisol was determined using a RIA (Cort-CT2, CIS bio
international, Gif-Sur-Yvette CEDEX, France) with intra-
and interassay CVof 3.8–4.6 and 4.4–5.5% respectively.Statistical analysis
Data are presented as meanGS.E.M. To compare cortisol
and IL6 between sexes a t-test was used. To assess
correlation a Pearson correlation was used. For
statistical analysis R, version 2.7.0 was used (9). To
obtain correlation confidence intervals (CI), the simple-
boot package was used (10). Bootstrap CI calculations
were based on 10 000 bootstrap replicates. To compare
IL6 versus cortisol regression slopes, the nlme package
was used (11).Results
Basal IL6 level was 0.84G0.10 pg/ml (0.75G
0.10 pg/ml male, 0.89G0.14 pg/ml female). Basal
cortisol was 351.9G18.3 nmol/l (351.9G24.5 nmol/l
male, 329.7G25.0 nmol/l female). Maximal cortisol
during the synacthen test was 653.0G20.6 nmol/l
(666.5G29.4 nmol/lmale,643.8G28.8 nmol/l female).
Maximal cortisol increment (Dcortisol) was 301.1G
20.0 nmol/l (282.3G30.4 nmol/l male, 314.1G
26.9 nmol/l female). There was no difference between
sexes in any of the parameters. IL6 concentrationwas not
correlated with basal or maximal cortisol concentration.
However, IL6 concentration was significantly correlated
with cortisol increment (all: rZ0.63, 95% CI 0.42–0.83,
P!0.01, male: rZ0.74, 95% CI 0.23–1.00, PZ0.01,
female: rZ0.56, 95% CI 0.28–0.81, PZ0.02, Fig. 1).www.eje-online.orgSlopes of the IL6 versus cortisol increment regression lines
did not differ between males and females (Fig. 1).Discussion
The aim of the study was to test whether adrenal cortex
response to ACTH in healthy humans correlates with
blood IL6 concentration. We postulated that higher
basal IL6 concentration would be associated with the
higher cortisol response to the stimulation. We decided
not to manipulate IL6 concentration, as IL6 influences
each level of the HPA axis. Instead, we used a low (1 mg)
ACTH test to assess the reactivity of the adrenal cortex.
In addition to the endocrine system, the neural and
immune systems are also involved in adrenal gland
regulation (12). Dissociation between central activation
of the HPA axis and the adrenal cortex can occur in a
variety of situations (13). In septic patients, a few days
after an insult, ACTH levels fall, but cortisol levels stay
high (14). In Trypanosoma cruzi infected mice there is an
increase in corticosterone, not accompanied by the
increase in ACTH (15).
IL6 is an important stimulator of the HPA axis. It has
the ability to influence each level of the HPA axis. IL6
induces CRH release from the hypothalamus of rats in a
dose-dependent manner (1, 2). In CRH knockout
animals, IL6 stimulates ACTH release, presumably by
binding to its own receptor on corticotrophs (3). In
humans, s.c. IL6 administration induced a dose-
dependent increase in ACTH and cortisol (6). IL6 also
acts directly on the adrenal cortex, stimulating
glucocorticoid release. Silverman et al., in an elegant
experiment, showed that ACTH is a necessary permiss-
ive factor enabling direct IL6 action on the adrenal
gland. In the presence of IL6, corticosterone response
was increased in wild-type mice and in CRH knockout
mice. However, in hypophysectomized animals cortisolDownloaded from Bioscientifica.com at 07/31/2019 03:09:27PM
via free access
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sampling showed that significant cross correlation
between IL6 and cortisol exists, IL6 preceding cortisol.
This was present both in physiologic and pathologic
conditions (16, 17).
In our study, we found that a relatively low plasma
IL6 concentration (0.84G0.10 pg/ml) in healthy
humans, modulates adrenal cortex response to ACTH
stimulation. Although IL6 concentration was not
correlated with the basal cortisol, it was significantly
correlated with the maximal cortisol increment (Dcor-
tisol, rZ0.63, 95% CI 0.42–0.83 P!0.01).
Therefore, subjects with higher plasma IL6 concen-
tration had higher cortisol response to ACTH stimu-
lation. This implies that, even under physiologic
conditions, IL6 modulates adrenal cortex response to
ACTH stimulation.
The major problem with this study is that this is a
correlation study. It is well known that spurious
correlations are possible. Some other factor e.g. IL1,
could influence the adrenal cortex (18). But in this case,
those factors would also be correlated with IL6. Also, a
large body of previously published data argues that the
influence of IL6 on cortisol secretion is significant.
Another possibility is false correlation due to an
unusual data distribution. However, bootstrap CI
shows that the obtained correlation is reliable, and
not caused by data distribution. Furthermore, dividing
the data by sex and analysing regression line slopes,
showed that slopes in males and females are the same,
arguing against unusual data distribution as a cause of
IL6 and cortisol increment correlation.
IL6 receptors are present in the adrenal cortex of
many species, including humans (3, 19–21). It has been
shown that IL6 alone stimulates glucocorticoid release
from primary cultures of rat, bovine and human adrenal
cells (19–23). However, in order to stimulate gluco-
corticoid release, a long incubation time (O12 h) is
required. IL6 also acts in synergy with ACTH, and in the
presence of ACTH IL6 increases glucocorticoid release
even at times when, alone, it is ineffective (19, 22). In
mice ACTH is a necessary permissive factor that enables
IL6 to stimulate glucocorticoid secretion, at least during
the first 36 h of viral infection (7). In both humans and
animals, during inflammatory response or IL6 treat-
ment, dissociation between central activation of the
HPA axis and the adrenal cortex secretion is found (14,
24–27).
In humans IL6 increases under different conditions,
such as exercise or sleep deprivation (17, 28). It was
shown that an increase in cytokines is associated with
insulin resistance and visceral obesity (29). Therefore, it
was proposed that IL6 is involved in the response to
somatic stress and in the development of obesity and
metabolic syndrome (16, 29). In obesity, there is a
dissociation between ACTH and cortisol secretion,
which is pronounced in the evening, (30) at approxi-
mately the same time the second zenith of IL6concentration occurs (31). Therefore, an IL6 induced
increase in cortisol secretion could be a part of the stress
response and could be involved in the development of
obesity, metabolic syndrome, fatigue and sleep disturb-
ances (16, 29). Our data support these hypotheses.
In our study, we found that a higher basal IL6
concentration is associated with the higher cortisol
response to ACTH stimulation. Based on previous
research and our data, IL6, even in low concentrations
and in physiologic conditions modulates adrenal cortex
responsivity to ACTH. Therefore, it seems that immune
modulation of HPA axis is present under physiologic and
not only pathologic conditions.Declaration of interest
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